Abstract: Ischemic conditions are a leading cause of death for both men and women, Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemic/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation.

Abstract: The present invention relates to novel biocompatible imaging particles comprising superparamagnetic iron oxide (SPIO) assembled into submicromiter-sized clusters within a biodegradable polycathecolamine or polyserotonine matrix, their synthesis and use in imaging techniques. These particles overcome the issues of toxicity and unreliable signal of the molecules from the prior art by providing similar contrast to that of the microparticles of iron oxide and rapidly disassemble into isolated SPIO particles once they reach the acidic lysosomal compartment of the MPS cells, thus enabling their digestion.

Abstract: Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemia/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation.

Abstract: The present invention relates to a biocompatible particle comprising nanoparticles of iron oxide embedded in a polycathecolamine or polyserotonine matrix, a suspension of said particles, a process for preparing said suspension of particles, a conjugate comprising said particle and the use of said particle and said conjugate in imaging techniques.

Abstract: Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemia/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood—brain barrier (BBB) after ischemic stroke and reduces inflammation.

Abstract: Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an pot ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For NI instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemia/reperfusion (UR) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation.

Abstract: Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).

Abstract: The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis.

Abstract: The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis.

Abstract: Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).

Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.

Abstract: Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).

Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.

Abstract: The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-as-partate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis.

Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.

Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.

Abstract: The invention relates to a protein or peptide consisting of a kringle protein or peptide and its use for the treatment of neurological or neurodegenerative disorders, in particular stroke. The invention relates also to an isolated antibody of fragment thereof which binds to the N-terminal domain of the NMDA receptor subunit NR1 (anti-NR1 antibody), whereas binding of the antibody or the fragment thereof prevents the cleavage of the extracellular domain of the NR1 subunit, or the fragment and its use for the treatment of neurological or neurodegenerative disorders, in particular stroke. The invention relates further to a pharmaceutical composition containing said kringle protein or peptide or anti-NR1 antibody.